Xenetic Biosciences, Inc. (OTCQB: XBIO) is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for the development of next generation biologic drugs that extend the efficacy, safety and half-life of biologic drugs and OncoHist™ for the development of novel oncology drugs focused on orphan indications.

Xenetic is working with Baxalta Incorporated (NYSE: BXLT), one of the Company’s largest shareholders, through an exclusive research, development and license agreement to develop a novel series of polysialylated blood coagulation factors, including a next generation Factor VIII. This collaboration relies on the PolyXen technology to conjugate PSA to therapeutic blood-clotting factors, with the goal of improving the pharmacokinetic profile and extending the active life of these biologic molecules.

Technology Platforms

Offers the potential of enhanced performance of peptide and protein drugs using polysialylation.

More about PolyXen


Established as novel, patent-protected, platform technology.

More about OncoHist

If you wish the view the Scheme Document and other related Documents, please click here.


Xenetic founder, Professor Gregory Gregoriadis, publishes semi-autobiography "Still the Cicadas Sing"

Product Pipeline

Xenetic is developing a biopharmaceutical pipeline with a multi-billion dollar market potential.

View our product candidates